What is the pharmaceutical regulatory framework in India?

India's pharmaceutical sector is regulated under the Drugs and Cosmetics Act 1940, Drugs and Cosmetics Rules 1945, and the Drugs (Prices Control) Order 2013. The CDSCO (Central Drugs Standard Control Organization) headed by DCGI (Drug Controller General of India) is the apex regulator. State Drug Control Departments handle state-level licensing. NPPA (National Pharmaceutical Pricing Authority) regulates prices of essential medicines.

What is CDSCO's role and what does DCGI approve?

CDSCO, established under the Drugs and Cosmetics Act 1940, regulates drug imports, new drug approvals, clinical trials, vaccines, and medical devices. DCGI heads CDSCO and approves: New Drug Applications (NDA), clinical trial protocols, vaccine approvals, medical device registrations under the Medical Devices Rules 2017, and import licences for finished formulations. State licensing authorities issue manufacturing licences in Form 25/28.

What licences are required to manufacture or import drugs in India?

Manufacturing requires a Form 25/28 licence from the State Licensing Authority for allopathic drugs. Import requires Form 10/10A (registration certificate and import licence) from CDSCO. WHO-GMP certification is needed for export markets. Clinical trials require Form CT-04A or CT-04B approval. Specific schedules (Schedule X for narcotic-containing drugs) require additional approvals. Medical devices follow MDR 2017 risk classification.

What are common pharmaceutical sector legal disputes?

Common disputes include: clinical trial regulatory rejections and protocol amendments, NPPA price control orders and overcharging recovery proceedings, drug patent infringement and Bolar exemption disputes, FDC (Fixed Dose Combination) bans by central government, manufacturing licence suspensions for GMP non-compliance, USFDA observations affecting Indian facilities, and competition law issues including pay-for-delay and excessive pricing investigations.

How does drug price control work under DPCO 2013?

The Drugs (Prices Control) Order 2013 empowers NPPA to fix ceiling prices for scheduled formulations listed in the National List of Essential Medicines (NLEM 2022 currently). Manufacturers must comply with notified ceiling prices and pay overcharged amount with 15% interest if exceeded. Non-scheduled drugs face Para 20 of DPCO 2013 — price increase capped at 10% per year. Para 19 allows extraordinary price control for any drug.

What are recent regulatory developments in Indian pharma?

Recent developments include: New Drugs and Clinical Trials Rules 2019 implementation, revised Schedule M for GMP compliance (with phased implementation), the Pharmacy (Amendment) Bill, ongoing Jan Aushadhi expansion, Medical Devices Amendment Rules 2024, CDSCO online portal SUGAM expansion, Bulk Drug Park scheme rollout, PLI scheme for pharma and KSMs/APIs/Biopharmaceuticals, and the proposed New Drugs, Medical Devices and Cosmetics Bill (replacing 1940 Act).

How does Bhatt & Joshi Associates assist pharmaceutical sector clients?

Bhatt & Joshi Associates advises pharma manufacturers, importers, and clinical research organisations on CDSCO/DCGI approvals, manufacturing licence disputes, NPPA price control matters, GMP/regulatory compliance, FDC ban challenges, and Schedule M implementation. Free consultation: +91 9824323743 or WhatsApp via https://bit.ly/ChatWithUs-BJ.

Pharma Lawyer India | CDSCO, DCGI, Drug Regulation

SECTORAL OVERVIEW OF PHARMACEUTICAL SECTOR IN INDIA : REGULATORY FRAMEWORK AND LEGAL SERVICES BY BHATT & JOSHI ASSOCIATES

With the pharmaceutical industry being heavily regulated, it is essential for companies in the sector to comply with the laws and regulations governing it. Bhatt & Joshi Associates provides legal services to pharmaceutical companies, helping them navigate the complex legal landscape and avoid any potential legal issues. The firm can assist with legal compliance, licensing and regulatory approvals, IP protection, contract drafting and negotiation, and litigation support. The firm’s experienced lawyers can provide legal guidance on matters related to drug pricing, patent disputes, clinical trials, and other legal issues faced by pharmaceutical companies. The pharmaceutical industry is one of the largest and most important industries in India, with the country being one of the largest manufacturers and exporters of generic drugs in the world.

LAWS GOVERNING THE PHARMA SECTOR

The Drugs & Cosmetics Act, 1940: This act regulates the import, manufacture, distribution, and sale of drugs in India. It establishes a system of dual regulatory control, with regulatory control at both central and state government levels.
The Pharmacy Act, 1948: This act is meant to regulate the profession of Pharmacy in India, including the education and training of pharmacists.
The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954: This act regulates the advertising of drugs, prohibiting the advertising of remedies alleged to possess magic qualities.
The Narcotic Drugs and Psychotropic Substances Act, 1985: This act is concerned with the control and regulation of operations relating to Narcotic Drugs and Psychotropic Substances.

With a growing demand for affordable and quality medicines, the pharma sector in India is expected to continue its growth trajectory in the years to come. However, the sector is heavily regulated by various laws and regulatory bodies, making it crucial for companies to seek legal guidance and support.

REGULATORY OVERVIEW:

The pharmaceutical sector in India is heavily regulated by various bodies to ensure the safety, efficacy, and affordability of drugs for the general public. Here are some of the key regulatory bodies that oversee the pharmaceutical sector in India:

Central Drugs Standard Control Organization (CDSCO): The CDSCO is the main regulatory body that approves and monitors the safety and efficacy of pharmaceutical products in India. It operates under the Ministry of Health & Family Welfare, Government of India and is responsible for the approval of new drugs, clinical trials, and the quality control of drugs already in the market.
Drug Controller General of India (DCGI): The DCGI is the head of the CDSCO and is responsible for regulating the import, manufacture, and sale of drugs in India. The DCGI also oversees the functioning of state-level drug regulatory authorities and ensures compliance with the Drugs and Cosmetics Act, 1940 and its Rules.
National Pharmaceutical Pricing Authority (NPPA): The NPPA is a government body responsible for fixing and regulating the prices of pharmaceutical products in India. It enforces the Drugs (Price Control) Order, 1995, and other orders related to price control issued by the government from time to time.
State Drug Regulatory Authorities: Each state in India has its own drug regulatory authority that regulates the manufacture, sale, and distribution of drugs within its jurisdiction. These authorities operate under the guidance of the CDSCO and ensure compliance with the Drugs and Cosmetics Act, 1940 and its Rules.

CONCLUSION

Overall, the regulatory framework for the pharmaceutical sector in India is complex and requires strict compliance with various laws and regulations. Bhatt & Joshi Associates, being a law firm, can provide legal services to pharmaceutical companies and other stakeholders in this sector, including regulatory and litigation support, contract drafting, and negotiation, compliance and risk management, and other advisory services to ensure compliance with various laws and regulations.